157 related articles for article (PubMed ID: 9919468)
1. Novel risk factors for vascular disease: the homocysteine hypothesis of cardiovascular disease.
Wilcken DE
J Cardiovasc Risk; 1998 Aug; 5(4):217-21. PubMed ID: 9919468
[TBL] [Abstract][Full Text] [Related]
2. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
[TBL] [Abstract][Full Text] [Related]
3. Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy.
Yap S; Naughten ER; Wilcken B; Wilcken DE; Boers GH
Semin Thromb Hemost; 2000; 26(3):335-40. PubMed ID: 11011851
[TBL] [Abstract][Full Text] [Related]
4. Folate, homocysteine, endothelial function and cardiovascular disease.
Moat SJ; Lang D; McDowell IF; Clarke ZL; Madhavan AK; Lewis MJ; Goodfellow J
J Nutr Biochem; 2004 Feb; 15(2):64-79. PubMed ID: 14972346
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine and vascular disease: nature or nurture?
Meleady RA; Graham IM
J Cardiovasc Risk; 1998 Aug; 5(4):233-7. PubMed ID: 9919471
[TBL] [Abstract][Full Text] [Related]
6. [Risk factors for cardiovascular diseases: what is the role for homocysteine?].
Bendini MG; Lanza GA; Mazza A; Giordano A; Leggio M; Menichini G; De Cristofaro R; Moriconi E; Cozzari L; Farina SM; Giordano G
G Ital Cardiol (Rome); 2007 Mar; 8(3):148-60. PubMed ID: 17461357
[TBL] [Abstract][Full Text] [Related]
7. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
8. Hyperhomocysteinemia: an additional cardiovascular risk factor.
Fanapour PC; Yug B; Kochar MS
WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials.
B-Vitamin Treatment Trialists' Collaboration
Am Heart J; 2006 Feb; 151(2):282-7. PubMed ID: 16442889
[TBL] [Abstract][Full Text] [Related]
10. Homocysteine and arterial thrombosis: Challenge and opportunity.
Di Minno MN; Tremoli E; Coppola A; Lupoli R; Di Minno G
Thromb Haemost; 2010 May; 103(5):942-61. PubMed ID: 20352150
[TBL] [Abstract][Full Text] [Related]
11. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P
Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
[TBL] [Abstract][Full Text] [Related]
12. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance.
Boers GH
Thromb Haemost; 1997 Jul; 78(1):520-2. PubMed ID: 9198207
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine and coronary heart disease.
Clarke R; Lewington S
Semin Vasc Med; 2002 Nov; 2(4):391-9. PubMed ID: 16222629
[TBL] [Abstract][Full Text] [Related]
14. [Hyperhomocysteinemia in coronary artery diseases. Apropos of a study on 102 patients].
Blacher J; Montalescot G; Ankri A; Chadefaux-Vekemans B; Benzidia R; Grosgogeat Y; Kamoun P; Thomas D
Arch Mal Coeur Vaiss; 1996 Oct; 89(10):1241-6. PubMed ID: 8952820
[TBL] [Abstract][Full Text] [Related]
15. Serum total homocysteine levels and the prevalence of folic acid deficiency and C677T mutation at the MTHFR gene in an indigenous population of Amazonia: the relationship of homocysteine with other cardiovascular risk factors.
Tavares EF; Vieira-Filho JP; Andriolo A; Perez AB; Vergani N; Sañudo A; Gimeno SG; Franco LJ
Ethn Dis; 2004; 14(1):49-56. PubMed ID: 15002923
[TBL] [Abstract][Full Text] [Related]
16. Hyperhomocysteinaemia and atherothrombosis.
Cattaneo M
Ann Med; 2000 Dec; 32 Suppl 1():46-52. PubMed ID: 11209982
[TBL] [Abstract][Full Text] [Related]
17. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials.
Splaver A; Lamas GA; Hennekens CH
Am Heart J; 2004 Jul; 148(1):34-40. PubMed ID: 15215789
[TBL] [Abstract][Full Text] [Related]
18. [Plasma homocysteine, a risk factor for premature vascular disease. Plasma levels in healthy persons; during pathologic conditions and drug therapy].
Ueland PM; Refsum H
Nord Med; 1989; 104(11):293-8. PubMed ID: 2813054
[TBL] [Abstract][Full Text] [Related]
19. Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2.
de Luis DA; Fernandez N; Arranz ML; Aller R; Izaola O; Romero E
J Diabetes Complications; 2005; 19(1):42-6. PubMed ID: 15642489
[TBL] [Abstract][Full Text] [Related]
20. Hyperhomocysteinemia in liver transplant recipients: prevalence and multivariate analysis of predisposing factors.
Herrero JI; Quiroga J; Sangro B; Beloqui O; Pardo F; Cienfuegos JA; Prieto J
Liver Transpl; 2000 Sep; 6(5):614-8. PubMed ID: 10980061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
